Study shows lifetime effects of pediatric liver transplants

Parents of pediatric liver transplant recipients report lower health-related quality of life for their children two years after the surgery, compared to reports from the parents of healthy children. However, reports of family dysfunction fall within the normal range. These findings are published in the April issue of Liver Transplantation.

Children account for up to 15 percent of liver transplant recipients each year in the U.S. Their 10-year survival rate is nearly 80 percent, however, survival is not the only outcome of interest. Liver transplantation has long-term implications for a child’s health related quality of life (HRQOL), which includes physical health, mental health, social functioning, role functioning and general health perceptions.

Previous studies have attempted to measure the HRQOL of pediatric liver transplant recipients, but have been limited to single centers and have yielded mixed results. Researchers from the Studies of Pediatric Liver Transplantation (SPLIT) consortium, led by Estella Alonso of Children’s Memorial Hospital in Chicago, decided to conduct a multi-center analysis of HRQOL and family function for these young patients.

They included 102 pediatric liver transplant recipients from five centers in the United States. Sixty-seven were under 5 years old, while 35 were between 5 and 18 years of age. At about 2 years post transplant, the researchers asked the children’s parents to complete a questionnaire about their child’s quality of life, along with the Family Assessment Devise (FAD), assessing family function. They then compared the data to either a control population or a published healthy normative population.

On measures of HRQOL, the younger transplant recipients scored significantly lower in global health, general health perceptions and change in health, compared to the children in the control group. The older children scored significantly lower in physical health, general health, parental emotional impact, and disruption of family activities.

Interestingly, however, the mean scores of the FAD scales indicated no increase in family dysfunction. Twenty-five percent of the transplant families were within the unhealthy range, compared to 19 to 36 percent of non-clinical families reported in FAD validation studies.

“Future assessments of HRQOL in this population should include the perspective of the patient and both of their parents to yield the fullest understanding of their health status and adjustment to post-transplant medical care,” the authors conclude.

Source: Blackwell Publishing

Related stories:

New treatment for hepatitis C
Researchers at the University of Oklahoma Health Sciences Center have found a new use for an old drug. Their findings appear online in the American Journal of Gastroenterology.
Studies test new approaches to islet transplantation
Researchers from 11 medical centers in the United States, Canada, Sweden, and Norway have begun testing new approaches to transplanting clusters of insulin-producing islets in adults with difficult-to-control type 1 diabetes. The clinical studies, funded by the National Institutes of Health (NIH), will determine whether changes to current methods of islet transplantation lead to improved, long-lasting control of blood glucose with fewer side effects.
A combination therapy of 3 vasodilators may treat portopulmonary hypertension
Combination therapy of Prostacyclin, Sildenafil, and Bosentan helped a young male patient with severe portopulmonary hypertension improve enough to receive a liver transplant. It was also used post-transplant to help him maintain his health. These findings are published in the March issue of Liver Transplantation, a journal by John Wiley & Sons.
Scientists confirm new virus responsible for deaths of transplant recipients in Australia
In the first application of high throughput DNA sequencing technology to investigate an infectious disease outbreak, scientists from Columbia University Mailman School of Public Health, the Victorian Infectious Diseases Reference Laboratory (VIRDL) in Melbourne, Australia, the Centers for Disease Control and 454 Life Sciences link the discovery of a new arenavirus to the deaths of three transplant recipients who received organs from a single donor in Victoria, Australia in April 2007. The full findings are published in the March 2008 issue of the New England Journal of Medicine and are now online.
Cord blood viable option for kids with life-threatening metabolic disorders
Children born with inherited metabolic disorders that cause organ failure and early death can be treated successfully with umbilical cord blood transplants from unrelated donors and, in some cases go on to live for many years, according to a study led by Duke University Medical Center researchers.
Genetic technology reveals how poisonous mushrooms cook up toxins
Heather Hallen spent eight years looking for poison in all the wrong places. Alpha-amanitin is the poison of the death cap mushroom, Amanita phalloides. The Michigan State University plant biology research associate was looking for a big gene that makes a big enzyme that produces alpha-amanitin, since that’s how other fungi produce similar compounds. But after years of defeat, she and her team called in the big guns – new technology that sequences DNA about as fast as a death cap mushroom can kill.
Inhaling nitric oxide helps transplant success
Administering inhaled nitric oxide (NO) during surgery helps protect liver transplant patients from organ failure, according to a new study from researchers at the University of Alabama at Birmingham (UAB).
1 in 7 organ donors concerned about life and health insurance
According to a new review in American Journal of Transplantation, people who donate their kidney or part of their liver to help someone else may themselves encounter difficulty with life and health insurance, despite insurance companies saying otherwise.

News discussion:

Medicine & Health news